BiotechTube

Apixaban 5 MG + Apixaban 2.5 MG + Warfarin

Phase 3Terminated
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aortic Valve Disease

Conditions

Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure

Trial Timeline

May 1, 2020 → Dec 12, 2022

NCT ID
NCT04142658

About Apixaban 5 MG + Apixaban 2.5 MG + Warfarin

Apixaban 5 MG + Apixaban 2.5 MG + Warfarin is a phase 3 stage product being developed by Artivion for Aortic Valve Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT04142658. Target conditions include Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04142658Phase 3Terminated

Competing Products

20 competing products in Aortic Valve Disease

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPhase 3
77
NOAC + DAPTDaiichi SankyoApproved
85
Ticagrelor + PlaceboAstraZenecaPhase 2
52
Rosuvastatin + PlaceboAstraZenecaPhase 3
77
candesartan + placeboAstraZenecaPhase 3
77
SugammadexMerckApproved
85
bisoprolol + placeboMerckApproved
85
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral TabletMerckPhase 2/3
65
Pelacarsen (TQJ230) 80mg + Matching placeboNovartisPhase 2
52
fluvastatinNovartisPhase 2
52
ACZ885 + PlaceboNovartisPhase 2
52
Evolocumab + PlaceboAmgenPhase 1
32
atorvastatin (Lipitor)PfizerApproved
84
Apixaban + Standard of carePfizerPhase 3
76
Ataciguat + PlaceboSanofiPhase 1
32
Ataciguat (HMR1766)SanofiPhase 2
51
Haemocomplettan® P + Saline solutionCSLPhase 2
51
Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)BayerPhase 3
74
Acetylsalicylic acid + Clopidogrel + RivaroxabanBayerPhase 3
74
DesfluraneBaxterApproved
82